27May 2020

CLINICAL SIGNIFICANCE AND PROGNOSTIC VALUE OF SURVIVIN AND P53 IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA

  • Sulaiman AlRajhi University, Al Bukayriyah, Kingdom of Saudi Arabia.
  • Clinical Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Crossref Cited-by Linking logo

  • Abstract
  • References
  • Cite This Article as
  • Corresponding Author

Background : Survivin is a member of the inhibitors of apoptosis (IAP) family , while P53 is a tumor suppressor protein which rapidly increases in response to cell stress , such as DNA damage. Both of Survivin and P53 are overexpressed in cancers including hematologic malignancy. Objective: To evaluate the level of survivin and P53 in children with acute lymphoblastic leukemia and to correlate it with clinical and hematological findings and response to treatment. Methods : The level of survivin was measured by ELISA and P53 expression was measured by flowcytometry in 37 children with acute lymphoblastic leukemia and 12 healthy children as a control group. The level of these two parameters was measured before and after treatment of patients and also correlated with clinical and hematological findings and response to treatment. Results : There was a highly significant difference in both serum survivin level and P53 expression between children with acute lymphoblastic leukemia at diagnosis compared to the control group , and the level has been significantly reduced after complete remission. Moreover , a significant positive correlation was found between serum survivin and LDH , WBCs count and percentage of blast cells in peripheral blood and bone marrow. Also , a significant positive correlation was found between survivin and P53 levels. Conclusion: The level of both survivin and P53 is significantly high in children with acute lymphoblastic leukemia and is positively correlated with poor prognostic factors , also survivin and P53 are positively correlated with each other.

  1. Harrison CJ. Acute lymphoblastic leukaemia. Best Pract Res Cl Ha. 2001;14:593?607.
  2. Ribera JM and Oriol A. Acute lymphoblastic leukemia in adolescents and young adults. Hematol Oncol Clin North Am. 2009;23(5):1033?42.
  3. Harms DO, Janka-Schaub GE, et al. Cooperative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92. Leukemia. 2000; 14:2234?2239.
  4. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. ??1995; 267:1456?1462..
  5. Fridman JS and Lowe SW.?? Control of apoptosis by p53. Oncogene. 2003;22:9030?40
  6. Nachmias B, Ashhab Y, Bucholtz V, Drize O, Kadouri L, Lotem M, et al. Caspase-mediated cleavage converts livin from an antiapoptotic to a pro-apoptotic factor: implications for drug-resistant melanoma. Cancer Res. 2003 ; 63:6340?9
  7. Song Z, Yao X and Wu M. Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis.?J Biol Chem.2003;278: 23130?23140
  8. Salman T, Argon A, Kebat T, Vardar E, Erkan N and Alacacıoğlu A. The prognostic significance of survivin expression in gallbladder carcinoma. APMIS. 2016;?124 : 633?638.
  9. R?del, J. Hoffmann, L. Distel, M. Herrmann, T. Noisternig, T. Papadopoulos et al.?? Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer.? Cancer Res, 65 .2005 ; 4881?4887
  10. Aref S, Salama O, Al-Tonbary Y, et al. Assessment of Bcl-2 expression as modulator of fas mediated apoptosis in acute leukemia. Hematology. 2004 ; 9 (2):113?121.
  11. Holleman A, Den Boer ML, Kazemier KM et al. : Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia. Blood. 2003? ;? 102:4541?4546
  12. Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, et al. Identification of p53 as a sequence-specific DNA-binding protein. Science. 1991 ; 252(5013):1708?11
  13. National Center for Biotechnology Information. The p53 tumor suppressor protein. Genes and Disease. United States National Institutes of Health Retrieved - 05-28 , 2008
  14. Vogelstein B, Lane D and Levine AJ.? Surfing the p53? ? Nature. 2000 ; 408 : 307?10.
  15. Bode AM and Dong Z.? Post-translational modification of p53 in tumorigenesis. Nat Rev? 2004 ; 4:793?805.
  16. Cavalcanti GB Jr,?da Cunha Vasconcelos F,?Pinto de Faria G,?Scheiner MA,?de Almeida Dobbin J,?Klumb CE and ?Maia RC.? Co-expression of p53 protein and MDR functional phenotype in leukemias: The predominant association in chronic myeloid leukemia.?Cytometry B Clin Cytom.?2004 ;?61B :?1?8.
  17. Salvesen G.S., and Duckett C.S. IAP proteins: blocking the road to death?s door. ?? Rev. Mol. Cell? Biol. 2002 ; 3:401-410.
  18. Troeger A., Siepermann M., Escherich G. et al. Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia. Haematologica. 2007 ; 92(8):1043-1050
  19. Hafiz M.G. and Mannan M.A. Serum lactate dehydrogenase level in childhood acute lymphoblastic leukemia. Bangladesh Med. Res. Counc. Bull. 2002 ;33(3):88-91
  20. Sadek H., Ragab S., Rasmy H., et al. Expression of the antiapoptotic gene? survivin in acute leukemia. ?? of?? Americ. Science. 2010 ; 6 (10): 1272-1282
  21. Raida S Yahya, Manal I Fouda, Hatim A El-Baz, ?Tamer E Mosa, ?and Mohamed?? D Abd ElMaksoud. Serum Survivin and TP53 Gene Expression in Children with Acute Lymphoblastic Leukemia. Iran J Public Health.? 2012 ;?41(1): 37?44
  22. Muhammad Al Makhbar and Almoutassem Billah Zetoune. Prognostic significance of serum survivin in Syrian childhood acute lymphoblastic leukemia , Journal of Chemical and Pharmaceutical Sciences. 2017 ;? 10 (2) : 980-82
  23. Oto OA, Paydas S, Tanriverdi K, Seydaoglu G, Yavuz S and Disel U.? Survivin and EPR-1 expression in acute leukemias: prognostic significance and review of the literature. Leuk Res. 2007; 31(11):1495?501
  24. Zhang L., Liu J., Lin H., et al. Expression of survivin, CDK4, Ki-67 and clinical significance in pediatric acute leukemia. Huazhong Univ. Sci. Technolog Med. Sci. 2006 ;26(5) : 552-554.
  25. Paydas S., Ergin M., Seydaoglu G., et al. Prognostic [corrected] significance of angiogenic/lymphangiogenic, anti-apoptotic, inflammatory and viral factors in 88 cases with diffuse large B cell lymphoma and review of the literature. Res. 2009 ;33(12): 1627-1635.
  26. Nakayama K. and Kamihira S. Survivin an important determinant for prognosis in adult T-cell leukemia: A novel biomarker in practical hemato-oncology. Lymphoma. 2002 ;43(12):2249-2255.
  27. Kamal Elden SM , Azzam A , Elbassal F , El‑Hawy MA and Saleh NY. Evaluation of survivin gene expression as a prognostic biomarker in pediatric B‑acute lymphoblastic leukemia.? Menoufia Medical Journal. 2018 ?; 31:952?956
  28. Haupt Y, Maya R, Kazaz A and Oren M. Mdm2 promote the rapid degradation of p53. Nature. 1997; 387:296?9
  29. Collot-Teixeira S, Bass J, Denis F and Ranger-Rogez S. Human tumor suppressor p53 and DNA viruses. Rev Med? 2004 ; 14:301?19.
  30. Abdelmoula-Souissi S, Rekik L, Gargouri A and Mokdad-Gargouri R. High-level expression of human tumour suppressor P53 in the methylotrophic yeast: Pichia pastoris. Protein Expres Purif. 2007; 54:283?8
  31. Park JS, Park TH, Lim YT, et al. Clinical significance of p53 protein overexpression and serum anti-p53 antibodies in patients with acute and chronic leukemia. Korean J Clin Pathol. 2000 ; 20:247-54.
  32. Mohamed Mohamed Abdel-Aziz . Clinical? Significance of Serum p53 and Epidermal Growth Factor Receptor in Patients with Acute Leukemia. Asian Pacific Journal of Cancer Prevention. 2013;14(7):4295-9
  33. Konikova E, Kusenda J and Babusikova O . Flow cytometry of p53 protein expression in some hematological malignancies. Neoplasma. 1999 ; 46, 368-76.
  34. Hui W, Zan Y, Wang X, Kang H, Guan H and Ma X. Expression of Survivin, p53 and its relationship with apoptosis, proliferation in hepatocellular carcinoma(HCC) Journal of Nanjing Medical University. 2008 ;22(4):255?9.

[Ahmad M. Hassaneen (2020); CLINICAL SIGNIFICANCE AND PROGNOSTIC VALUE OF SURVIVIN AND P53 IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA Int. J. of Adv. Res. 8 (May). 357-366] (ISSN 2320-5407). www.journalijar.com

Ahmad M. Hassaneen
1-Sulaiman AlRajhi University , Al Bukayriyah, Kingdom of Saudi Arabia , 2-Clinical Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

DOI:

Article DOI: 10.21474/IJAR01/10931      
DOI URL: https://dx.doi.org/10.21474/IJAR01/10931

Download Full Paper

Download PDF No. of Downloads: 24 | No. of Views: 57